HRD HSCT Shows Promise Among Pediatric Patients With Hematologic Cancers

Among pediatric patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT), using haploidentical-related donor (HRD) sources with post-transplant cyclophosphamide may yield similar outcomes to those seen with umbilical cord blood (UCB), according to research published in Blood Research.

Read more: https://www.oncologynurseadvisor.com/news/hrd-stem-cell-hsct-hematologic-cancer-pediatric-patients-treatment-risk/